[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Melanocyte Stimulating Hormone Receptor - Pipeline Review, H1 2020

April 2020 | 76 pages | ID: MA9A8FBCA8DEEN
Global Markets Direct

US$ 3,500.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Melanocyte Stimulating Hormone Receptor - Pipeline Review, H1 2020

SUMMARY

According to the recently published report 'Melanocyte Stimulating Hormone Receptor - Pipeline Review, H1 2020'; Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) pipeline Target constitutes close to 12 molecules.

Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Melanocyte-stimulating hormone receptor (MSHR) also known as melanocortin 1 receptor (MC1R), is a G protein-coupled receptor that binds to a peptide hormones known as the melanocortins, which include adrenocorticotropic hormone (ACTH). When activated by alpha-MSH, MC1R initiates a complex signaling cascade that leads to the production of the brown or black pigment eumelanin. The receptor also antagonize by agouti signaling peptide which reverts the cell back to producing the yellow or red phaeomelanin.

The report 'Melanocyte Stimulating Hormone Receptor - Pipeline Review, H1 2020' outlays comprehensive information on the Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 3, 1, 5 and 1 respectively.

Report covers products from therapy areas Dermatology, Gastrointestinal, Genito Urinary System And Sex Hormones, Metabolic Disorders, Central Nervous System, Genetic Disorders, Immunology, Musculoskeletal Disorders, Ophthalmology, Infectious Disease, Oncology and Respiratory which include indications Diabetic Retinopathy, Inflammatory Bowel Disease, Multiple Sclerosis, Porphyria (Erythropoietic Protoporphyri), Rheumatoid Arthritis, Uveitis, Vitiligo, Acute Respiratory Distress Syndrome, Coronavirus Disease 2019 (COVID-19), Gouty Arthritis (Gout), IgA Nephropathy (Berger's Disease), Infantile Spasm (West Syndrome), Keratoconjunctivitis Sicca (Dry Eye), Kidney Disease (Nephropathy), Metastatic Melanoma, Nephrotic Syndrome, Peritonitis, Porphyria Variegata, Psoriatic Arthritis, Systemic Lupus Erythematosus and Ulcerative Colitis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape for Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R)
  • The report reviews Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) targeted therapeutics
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Overview
Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Companies Involved in Therapeutics Development
Aequus BioPharma Inc
Clinuvel Pharmaceuticals Ltd
Eton Pharmaceuticals Inc
Mallinckrodt Plc
Mitsubishi Tanabe Pharma Corp
Palatin Technologies Inc
SynAct Pharma AB
Viewpoint Molecular Targeting LLC
Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Drug Profiles
afamelanotide acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AP-1189 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AQB-565 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
corticotropin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
corticotropin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CUV-9900 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dersimelagon - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Parvysmelanotide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptide to Antagonize MCR1 for Metastatic Melanoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PL-8177 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PL-8331 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PL-9643 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Dormant Products
Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Discontinued Products
Melanocyte Stimulating Hormone Receptor (Melanocortin Receptor 1 or MSHR or MC1R) - Product Development Milestones
Featured News & Press Releases
Apr 23, 2020: SCENESSE to be Prescribed in China
Apr 16, 2020: First US patients to be treated with SCENESSE
Apr 16, 2020: Innovative drug launched for rare, isolating, “light intolerance” disorder
Apr 15, 2020: Mallinckrodt announces publication of data on Acthar Gel (Repository Corticotropin Injection) from its randomized, double-blind, placebo-controlled phase 4 study in rheumatoid arthritis (RA) in Rheumatology and Therapy
Apr 03, 2020: SynAct Pharma applies for patent for AP1189 within COVID-19
Mar 31, 2020: SynAct Pharma submits clinical trial application for AP1189 in Nephrotic Syndrome
Mar 31, 2020: SynAct Pharma investigates the possibility of AP1189 as additional therapy in hospitalized patients with COVID-19
Mar 16, 2020: Mallinckrodt confirms court decision in lawsuit against U.S. Department of Health and Human Services (HHS) and Centers for Medicare and Medicaid Services (CMS) and provides update related to global opioid settlement and present financing activities
Mar 05, 2020: Data on Acthar Gel (repository corticotropin injection) therapy in immunoglobulin a nephropathy (IgAN) published in Kidney International Reports
Mar 04, 2020: Mallinckrodt announces publication of new data on Acthar Gel (Repository Corticotropin Injection) in rheumatoid arthritis, systemic lupus erythematosus and dermatomyositis/polymyositis published in Open Access Rheumatology: Research and Reviews
Mar 03, 2020: FDA meeting confirmed to advance SCENESSE in vitiligo
Mar 02, 2020: Supply of Scenesse unaffected by coronavirus
Feb 27, 2020: Mallinckrodt to present new data from two studies on Acthar Gel (Repository Corticotropin Injection) therapy in Multiple Sclerosis (MS) relapse at Fifth Annual ACTRIMS Forum 2020
Feb 19, 2020: Palatin Technologies announces first patient enrolled in dry eye disease phase 2 clinical trial with PL9643
Feb 10, 2020: Request for FDA guidance meeting SCENESSE in Vitiligo
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indications, H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by Aequus BioPharma Inc, H1 2020
Pipeline by Clinuvel Pharmaceuticals Ltd, H1 2020
Pipeline by Eton Pharmaceuticals Inc, H1 2020
Pipeline by Mallinckrodt Plc, H1 2020
Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2020
Pipeline by Palatin Technologies Inc, H1 2020
Pipeline by SynAct Pharma AB, H1 2020
Pipeline by Viewpoint Molecular Targeting LLC, H1 2020
Dormant Products, H1 2020
Dormant Products, H1 2020 (Contd..1), H1 2020
Discontinued Products, H1 2020

LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Mechanism of Actions, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020

COMPANIES MENTIONED

Aequus BioPharma Inc
Clinuvel Pharmaceuticals Ltd
Eton Pharmaceuticals Inc
Mallinckrodt Plc
Mitsubishi Tanabe Pharma Corp
Palatin Technologies Inc
SynAct Pharma AB
Viewpoint Molecular Targeting LLC


More Publications